597 related articles for article (PubMed ID: 30665953)
1. Sodium-Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease.
Alicic RZ; Neumiller JJ; Johnson EJ; Dieter B; Tuttle KR
Diabetes; 2019 Feb; 68(2):248-257. PubMed ID: 30665953
[TBL] [Abstract][Full Text] [Related]
2. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review.
Alicic RZ; Johnson EJ; Tuttle KR
Am J Kidney Dis; 2018 Aug; 72(2):267-277. PubMed ID: 29866460
[TBL] [Abstract][Full Text] [Related]
3. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease.
Mima A
J Diabetes Complications; 2018 Jul; 32(7):720-725. PubMed ID: 29880432
[TBL] [Abstract][Full Text] [Related]
4. SGLT2 Inhibitors and the Diabetic Kidney.
Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
[TBL] [Abstract][Full Text] [Related]
5. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
[TBL] [Abstract][Full Text] [Related]
6. SGLT-2 inhibitors in Diabetic Kidney Disease: What Lies Behind their Renoprotective Properties?
Georgianos PI; Divani M; Eleftheriadis T; Mertens PR; Liakopoulos V
Curr Med Chem; 2019; 26(29):5564-5578. PubMed ID: 29792136
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis.
Zhang XL; Zhu QQ; Chen YH; Li XL; Chen F; Huang JA; Xu B
J Am Heart Assoc; 2018 Jan; 7(2):. PubMed ID: 29353233
[TBL] [Abstract][Full Text] [Related]
8. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
Tuttle KR; Brosius FC; Cavender MA; Fioretto P; Fowler KJ; Heerspink HJL; Manley T; McGuire DK; Molitch ME; Mottl AK; Perreault L; Rosas SE; Rossing P; Sola L; Vallon V; Wanner C; Perkovic V
Am J Kidney Dis; 2021 Jan; 77(1):94-109. PubMed ID: 33121838
[TBL] [Abstract][Full Text] [Related]
9. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
[TBL] [Abstract][Full Text] [Related]
10. The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes.
Jaikumkao K; Pongchaidecha A; Chatsudthipong V; Chattipakorn SC; Chattipakorn N; Lungkaphin A
Biomed Pharmacother; 2017 Oct; 94():176-187. PubMed ID: 28759755
[TBL] [Abstract][Full Text] [Related]
11. Role of sodium-glucose cotransporter 2 inhibition to mitigate diabetic kidney disease risk in type 1 diabetes.
van Raalte DH; Bjornstad P
Nephrol Dial Transplant; 2020 Jan; 35(Suppl 1):i24-i32. PubMed ID: 32003832
[TBL] [Abstract][Full Text] [Related]
12. Renal effects of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and renal impairment.
Weir MR
Postgrad Med; 2019 Aug; 131(6):367-375. PubMed ID: 31132013
[TBL] [Abstract][Full Text] [Related]
13. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis.
Packer M
Diabetes Obes Metab; 2018 Jun; 20(6):1361-1366. PubMed ID: 29359851
[TBL] [Abstract][Full Text] [Related]
14. Sodium-glucose Cotransporter 2 Inhibitors: Nephroprotective Impact on Diabetic Kidney Disease.
Stavropoulos K; Imprialos KP; Stavropoulos N; Bouloukou S; Kerpiniotis G; Dimitriadis K; Tsioufis C; Doumas M
Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):120-126. PubMed ID: 29412122
[TBL] [Abstract][Full Text] [Related]
15. Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease.
Górriz JL; Navarro-González JF; Ortiz A; Vergara A; Nuñez J; Jacobs-Cachá C; Martínez-Castelao A; Soler MJ
Nephrol Dial Transplant; 2020 Jan; 35(Suppl 1):i13-i23. PubMed ID: 32003834
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease.
Scheen AJ
Expert Opin Drug Saf; 2020 Mar; 19(3):243-256. PubMed ID: 32083962
[No Abstract] [Full Text] [Related]
17. SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases.
Wanner C; Marx N
Diabetologia; 2018 Oct; 61(10):2134-2139. PubMed ID: 30132035
[TBL] [Abstract][Full Text] [Related]
18. SGLT2 inhibition and kidney protection.
Nespoux J; Vallon V
Clin Sci (Lond); 2018 Jun; 132(12):1329-1339. PubMed ID: 29954951
[TBL] [Abstract][Full Text] [Related]
19. SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects.
Garofalo C; Borrelli S; Liberti ME; Andreucci M; Conte G; Minutolo R; Provenzano M; De Nicola L
Medicina (Kaunas); 2019 Jun; 55(6):. PubMed ID: 31212638
[TBL] [Abstract][Full Text] [Related]
20. Impact of SGLT2 inhibitors on the kidney in people with type 2 diabetes and severely increased albuminuria.
Shah N; Perkovic V; Kotwal S
Expert Rev Clin Pharmacol; 2022 Jul; 15(7):827-842. PubMed ID: 35912871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
